Abstract:Objective To explore the susceptibility of Aspergillus biofilms to common antifungal drugs and molecular mechanisms of antifungal drug resistance of Aspergillus biofilms. Methods The susceptibility of planktonic spores of 22 clinical isolates of Aspergillus spp. to amphotericin B, caspofungin and voriconazole was evaluated by a standard broth microdilution method. Meanwhile, in vitro model of Aspergillus spp. biofilm was established for the 22 isolates, then the susceptibility of Aspergillus spp. biofilm to amphotericin B, caspofungin and voriconazole was evaluated by a method for antifungal susceptibility testing combined with colonmetric XTT-reduction assay. In addition, real-time reverse transcription (RT)-PCR was performed to determine the relative expressions of drug efflux pump genes and azole target enzyme genes during the formation of Aspergillus spp. biofilms. Results In terms of planktonic spores of Aspergillus spp., the- minimal inhibitory concentration (MIC) range was 0.5 to 2 mg/L for amphotericin B, 0.5 to 1 mg/L for voriconazole, and the minimal effective concentration (MEC) range was 0.125 to 0.25 mg/L for caspofungin. As far as Aspergillus spp.biofilms was concerned, the sessile minimum concentration required to inhibit the growth of 50% organisms (SMIC50) and 80% organisms (SMIC80) ranged from 2 to > 32 mg/L and from 8 to > 32 mg/L, respectively, for amphotericin B, from 32 to > 256 mg/L and from 256 to >256 mg/L respectively for caspofungin, from 4 to >256 mg/L and from 32 to > 256 mg/L, respectively for voriconazole. During the formation of Aspergillus spp.biofilms, no change was observed for the expression of any of the 7 tested drug efflux pump genes or azole target enzyme genes at 4 hours, while a significant increase was noted in the expression of AfuMDRl, CYP51B and CYP51A genes at 8 hours, as well as in the expression of AfuMDRl, AfuMDR2, AfuMDR4, CYP51A,CYP51B at 12, 16 and 24 hours. Of these genes, CYP51A showed the strongest increase in expression at the above 4 time points. The expression of AfuMDR3 and atrF experienced no significant change during the formation of Aspergillus spp. biofilms. Conclusions Compared to planktonic spores, Aspergillus spp. biofilms exhibit a decreased susceptibility to amphotericin B, caspofungin and voriconazole. After the formation of biofilms, the expression of drug efflux pump genes and azole target enzyme genes is elevated in Aspergillus spp.

In Vitro Activity of Ibuprofen Against Clinical Isolates of Aspergillus

Antifungal Activity of Statins Against Aspergillus Species.

In vitro effects of lovastatin and simvastatin against clinical isolates of Aspergillus species

In Vitro Antifungal Activity of Farnesyltransferase Inhibitors Against Clinical Isolates of Aspergillus and Candida

In Vitro Activity of 23 Antifungal Drugs against 54 Clinical and Environmental Aspergillus oryzae isolates

In vitro antifungal activity of micafungin against clinical strains of Candida spp. and Aspergillus spp. isolated from China

Antifungal susceptibility testing of clinical isolates of itraconazole-resistant Aspergillus fumigatus to four antifungal drugs

MIC and fungicidal activity of terbinafine against clinical isolates of Aspergillus spp

Antifungal compounds from Bacillus subtilis B-FS06 inhibiting the growth of Aspergillus flavus

Susceptibility testing of Aspergillus biofilms against common antifungal drugs and a preliminary study on molecular mechanisms of antifungal drug resistance in Aspergillus biofilms

Identification of B-FS06 and the Antagonistic Activity of Its Cultural Productions Against Aspergillus Flavus

In vitro antifungal susceptibility profile and genotypic characterization of clinical Aspergillus isolates in Eastern China on behalf of Eastern China Invasive Fungi Infection Group (ECIFIG)

Antifungal susceptibility test for pathogenic Fusarium spp in vitro

Comparison of susceptibility testing by EUCAST and CLSI broth microdilution methods against Aspergillus isolates

In vitro antifungal activity of amphotericin B and 11 comparators against Aspergillus terreus species complex

In Vitro Activities of Five Antifungal Agents Against Pathogenic Exophiala Species

Preliminary study on the susceptibility of a polyene-resistant Aspergillus flavus strain to common antifungal drugs

In vitro activities of flutrimazole against fungal pathogens isolated from tinea pedis

In Vitro Antifungal Activity of Selected Essential Oils against Drug-Resistant Clinical Aspergillus spp. Strains

Evaluation of in Vitro Antifungal Activities of Bifonazole-triamcinolone Acetonide Against Dermatophytes

Antifungal and Antivirulence Activity of Vanillin and Tannic Acid Against Aspergillus fumigatus and Fusarium solani